SCHEMBL22980204

SCHEMBL22980204

COC(=O)OC(=O)C(COCc1ccccc1)NC(=O)OC(C)(C)C

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.69
CTSS P25774 4/20 0.65
PPARG P37231 2/20 0.64
KLK5 Q9Y337 3/20 0.60
KLK7 P49862 2/20 0.60
SYK P43405 1/20 0.51
RAB9A P51151 1/20 0.51
CTSK P43235 2/20 0.49
CTSL P07711 1/20 0.49
CTSB P07858 1/20 0.49
REN P00797 1/20 0.49
ACE P12821 1/20 0.47
PTPN1 P18031 3/20 0.47
CDC25B P30305 3/20 0.47
PTPN2 P17706 2/20 0.47
CDC25A P30304 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22980203 1.00 PPARA (0.69) PPARACTSSPPARGKLK5KLK7
SCHEMBL9743961 0.94 PPARA (0.74) PPARACTSSPPARGKLK5KLK7
SCHEMBL2948481 0.91 PPARA (0.74) PPARACTSSPPARGKLK5KLK7
SCHEMBL2948482 0.91 PPARA (0.74) PPARACTSSPPARGKLK5KLK7
SCHEMBL5249102 0.91 PPARA (0.74) PPARACTSSPPARGKLK5KLK7
SCHEMBL7518373 0.89 PPARA (0.74) PPARACTSSPPARGKLK5KLK7
SCHEMBL19853661 0.89 PPARA (0.74) PPARACTSSPPARGKLK5KLK7
SCHEMBL1132901 0.86 PPARA (0.90) PPARACTSSPPARGKLK5KLK7
SCHEMBL17051 0.86 PPARA (0.90) PPARACTSSPPARGKLK5KLK7
SCHEMBL828674 0.86 PPARA (0.90) PPARACTSSPPARGKLK5KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010329-B9 DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-10-04 EP disclosed
EP-4010329-B1 DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-06-07 EP disclosed
US-20220259174-A1 DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2022-08-18 US disclosed
CN-114846003-A Deuterated compounds for the treatment of cancer 阿提奥斯医药有限公司 2022-08-02 CN disclosed
EP-4010329-A1 DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2022-06-15 EP disclosed
WO-2021028670-A1 DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259174-A1 DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, HCCS PPARA 342/4885CTSS 2770/4885PPARG 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.